

Contents

Contributors	page vii
Foreword by Sir Gregory Winter	xi
Preface	xiii
PART I. HUMANIZED ANTIBODIES	
1 Humanization of Recombinant Antibodies <i>José W. Saldanha</i>	3
2 Immunogenicity Assessment of Antibody Therapeutics <i>Philippe Stas, Jurgen Pletinckx, Yannick Gansemans, and Ignace Lasters</i>	20
3 <i>In Vitro</i> Screening for Antibody Immunogenicity <i>Frank J. Carr and Matthew P. Baker</i>	43
PART II. GENERATION AND SCREENING OF ANTIBODY LIBRARIES	
4 Antibody Libraries from Naïve V Gene Sources <i>Gerald Beste and David Lowe</i>	55
5 Antibodies from IgM Libraries <i>Stefan Knackmuss and Vera Molkenthin</i>	66
6 Generation and Screening of the Synthetic Human Combinatorial Antibody Library HuCAL GOLD <i>Ingo M. Klagge</i>	75
PART III. TRANSGENIC HUMAN ANTIBODY REPERTOIRES	
7 Therapeutic Antibodies from XenoMouse Transgenic Mice <i>Aya Jakobovits</i>	89
8 VelocImmune: Immunoglobulin Variable Region Humanized Mice <i>Andrew Murphy</i>	100
PART IV. ANTIBODY EFFECTOR FUNCTION	
9 Mechanisms of Tumor Cell Killing by Therapeutic Antibodies <i>Ross Stewart and Carl Webster</i>	111
10 Optimization of Fc Domains to Enhance Antibody Therapeutics <i>Greg A. Lazar and Aaron K. Chamberlain</i>	124
11 Glycoengineered Therapeutic Antibodies <i>Peter Brünker, Peter Sondermann, and Pablo Umaña</i>	144

PART V. ARMING ANTIBODIES		
12	Monoclonal Antibodies for the Delivery of Cytotoxic Drugs <i>David J. King</i>	157
13	Immunotherapy with Radio-immune Conjugates <i>Christina A. Kousparou and Agamemnon A. Epenetos</i>	174
14	Immunotherapeutic Antibody Fusion Proteins <i>Nigel S. Courtenay-Luck and David Jones</i>	190
PART VI. NOVEL ANTIBODY FORMATS		
15	Alternative Antibody Formats <i>Fabrice Le Gall and Melvyn Little</i>	203
16	Single-Domain Antibodies <i>Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens</i>	216
17	Engineering of Non-CDR Loops in Immunoglobulin Domains <i>Florian Rüker and Gordana Wozniak-Knopp</i>	231
PART VII. ANTIGEN-BINDING REPERTOIRES OF NON-IMMUNOGLOBULIN PROTEINS		
18	Alternative Scaffolds: Expanding the Options of Antibodies <i>Andreas Plückthun</i>	243
PART VIII. PROLONGATION OF SERUM HALF-LIFE		
19	Polymer Fusions to Increase Antibody Half-Lives: PEGylation and Other Modifications <i>Sam P. Heywood and David P. Humphreys</i>	275
20	Extending Antibody Fragment Half-Lives with Albumin <i>Jan Terje Andersen and Inger Sandlie</i>	293
PART IX. INNOVATIVE IMMUNOTHERAPEUTIC APPROACHES		
21	A Stem Cell–Based Platform for the Discovery and Development of Antitumor Therapeutic Antibodies to Novel Targets <i>Jennie P. Mather, Claudia Fieger, Tony W. Liang, Kathleen L. King, Jonathan Li, Peter Young, Claude Beltejar, Beverly Potts, Monica Licea, and Deryk Loo</i>	313
22	Antibody Directed Enzyme Prodrug Therapy (ADEPT) <i>Helen L. Lowe, Surinder K. Sharma, Kenneth D. Bagshawe, and Kerry A. Chester</i>	336
23	Immune Privilege and Tolerance – Therapeutic Antibody Approaches <i>Daron Forman, Paul Ponath, Devangi Mehta, Joe Ponte, Jessica Snyder, Patricia Rao, Herman Waldmann, and Michael Rosenzweig</i>	350
PART X. MARKET OVERVIEW AND OUTLOOK		
24	Antibody Therapeutics: Business Achievements and Business Outlook <i>Christophe Bourrilly</i>	373
	Index	403
<i>Color plates follow page xvi.</i>		